Drug
Sustained Release Desvenlafaxine
Sustained Release Desvenlafaxine: highest development phase Phase 2/3, developed by Hansoh Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Hansoh Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Sustained-Release Desvenlafaxine Hydrochloride NCT01977378 | Phase 2/3 | Major Depressive Disorder |
Latest
No recent events.
Follow Sustained Release Desvenlafaxine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.